ArticleNeuro-oncology advances

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies.

Yazmin Odia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.